ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Company profile
Ticker
ACAD
Exchange
Website
CEO
Mr. Stephen R. Davis J.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
ACADIA Pharmaceuticals A/S • ACADIA Pharmaceuticals GmbH • ACADIA Pharma Limited • CerSci Therapeutics Incorporated • Amorsa Therapeutics Inc. • Acadia Pharmaceuticals Holdings Inc. • Levo Therapeutics, Inc. ...
IRS number
61376651
ACAD stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
23 Sep 24
8-K
Departure of Directors or Certain Officers
23 Sep 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Aug 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Aug 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Aug 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Aug 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Aug 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Aug 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Aug 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Aug 24
Transcripts
ACAD
Earnings call transcript
2024 Q2
6 Aug 24
ACAD
Earnings call transcript
2024 Q1
8 May 24
ACAD
Earnings call transcript
2023 Q4
27 Feb 24
ACAD
Earnings call transcript
2023 Q3
2 Nov 23
ACAD
Earnings call transcript
2023 Q2
2 Aug 23
ACAD
Earnings call transcript
2023 Q2
2 Aug 23
ACAD
Earnings call transcript
2023 Q1
8 May 23
ACAD
Earnings call transcript
2022 Q4
27 Feb 23
ACAD
Earnings call transcript
2022 Q3
3 Nov 22
ACAD
Earnings call transcript
2022 Q2
9 Aug 22
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 182.90 mm | 182.90 mm | 182.90 mm | 182.90 mm | 182.90 mm | 182.90 mm |
Cash burn (monthly) | 9.20 mm | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 34.56 mm | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 148.34 mm | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 16.1 | n/a | n/a | n/a | n/a | n/a |
Institutional ownership, Q2 2024
96.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 263 |
Opened positions | 48 |
Closed positions | 43 |
Increased positions | 104 |
Reduced positions | 77 |
13F shares | Current |
---|---|
Total value | 2.56 tn |
Total shares | 160.70 mm |
Total puts | 257.30 k |
Total calls | 722.80 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Baker Bros. Advisors | 42.88 mm | $696.77 bn |
Vanguard | 13.71 mm | $222.82 bn |
RTW Investments | 13.71 mm | $222.75 bn |
BLK BlackRock | 12.06 mm | $196.01 bn |
STT State Street | 5.80 mm | $94.26 bn |
Point72 Asset Management | 3.71 mm | $60.29 bn |
Millennium Management | 2.94 mm | $47.74 bn |
D. E. Shaw & Co. | 2.93 mm | $47.69 bn |
Geode Capital Management | 2.84 mm | $46.24 bn |
Marshall Wace | 2.77 mm | $45.08 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Oct 24 | Adora Ndu | Common Stock | Option exercise | Acquire M | No | No | 0 | 4,381 | 0.00 | 15,414 |
12 Oct 24 | Adora Ndu | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 4,381 | 0.00 | 0 |
23 Sep 24 | Catherine E. Owen | Stock Option Common Stock | Grant | Acquire A | No | No | 16.29 | 353,261 | 5.75 mm | 353,261 |
19 Aug 24 | Davis Stephen | Common Stock | Sell | Dispose S | No | Yes | 15.28 | 31,747 | 485.09 k | 186,555 |
19 Aug 24 | Brendan Teehan | Common Stock | Sell | Dispose S | No | Yes | 15.28 | 9,534 | 145.68 k | 52,177 |
16 Aug 24 | Davis Stephen | Common Stock | Grant | Acquire A | No | No | 0 | 44,782 | 0.00 | 218,302 |
16 Aug 24 | Davis Stephen | Common Stock | Grant | Acquire A | No | No | 0 | 17,333 | 0.00 | 173,520 |
16 Aug 24 | Brendan Teehan | Common Stock | Grant | Acquire A | No | No | 0 | 13,629 | 0.00 | 61,711 |
16 Aug 24 | Brendan Teehan | Common Stock | Grant | Acquire A | No | No | 0 | 5,024 | 0.00 | 48,082 |
News
Critical Insights From ACADIA Pharmaceuticals Analyst Ratings: What You Need To Know
10 Oct 24
Raymond James Reinstates Market Perform on ACADIA Pharmaceuticals
10 Oct 24
Acadia Healthcare Company To Pay $19.85M To Settle Allegations Relating To Medically Unnecessary Inpatient Behavioral Health Services
26 Sep 24
What's Going On With ACADIA Pharmaceuticals Stock?
24 Sep 24
Axcelead Drug Discovery Partners Enters Into Master Service Agreement For Drug Discovery Projects With Acadia Pharmaceuticals To Support Their Goal Of Discovering And Developing Innovative And Novel Medicines To Help Address Unmet Medical Needs; No Financial Terms Disclosed
19 Sep 24
Press releases
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
17 Oct 24
Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome
16 Oct 24
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8 Oct 24
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26 Sep 24
Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals
23 Sep 24